UCM-1306

• Description :

  UCM-1306 is a potent and orally active human dopamine D1 receptor allosteric modulator (PAM) . UCM-1306 increases the endogenous dopamine (DA) maximal effect both in human and mouse D1 receptors. UCM-1306 is not only for improving motor symptoms but also for addressing the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD) [1].

• UNSPSC :

  12352005

• Target :

  Dopamine Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  Neuroscience-Neurodegeneration

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/ucm-1306.html

• Purity :

  99.61

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  O=S(C1=CC=C(C2=C(OCF)C=CC=C2)C=C1)(C)=N

• Molecular Formula :

  C14H14FNO2S

• Molecular Weight :

  279.33

• References & Citations :

  [1]García-Cárceles J, et, al. 2- (Fluoromethoxy) -4'- (S-methanesulfonimidoyl) -1,1'-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D1 Receptor for Parkinson's Disease. J Med Chem. 2022 Sep 22;65 (18) :12256-12272.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2258608-78-3]